Cameron Santoro

Cameron Santoro is an associate editor for The Center for Biosimilars®, The American Journal of Managed Care® (AJMC), and AJMC.com.


Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

May 11, 2025

Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to lower costs, and a possible lower immunogenicity profile.

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

May 06, 2025

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access

April 28, 2025

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.